tldrdailynews.com logo
Tag

Obesity Treatment

All articles tagged with #obesity treatment

Move More, Think Well: Exercise and Mental Health Key to GLP-1 Weight Loss
health12 days ago

Move More, Think Well: Exercise and Mental Health Key to GLP-1 Weight Loss

GLP-1 weight-loss injections can jump-start shedding pounds, but long-term success hinges on lifestyle: regular exercise, better food choices, adequate sleep, and attention to mental health. One patient lost 110 pounds after adding a six-days-a-week workout plan. Doctors warn about potential complications (pancreatitis, gallstones, kidney injury) if dosage is increased too quickly or misused, underscoring the need for medical supervision. Access and cost remain barriers, with limited insurance coverage for obesity and forthcoming Medicare coverage; online suppliers may lack dosing guidance and safety information.

via Daily Kos|
#exercise#glp-1#health
Stopping Ozempic and Wegovy Typically Reverses Weight Loss Within 1.5 Years
health2 months ago

Stopping Ozempic and Wegovy Typically Reverses Weight Loss Within 1.5 Years

A Wall Street Journal piece explains that GLP-1 weight-loss medications like Ozempic and Wegovy are intended as lifelong treatments for obesity, not quick lifestyle fixes; studies show most people who stop the drugs regain the lost weight within about 1.5 years, underscoring the need for ongoing treatment and monitoring.

via The Wall Street Journal|
#glp-1-weight-loss-drugs#health#obesity-treatment
Real-world GLP-1 weight loss often endures after stopping therapy
health2 months ago

Real-world GLP-1 weight loss often endures after stopping therapy

A real-world analysis of 135,000+ patients on GLP-1 therapies (tirzepatide and semaglutide) found weight loss durability after discontinuation. Six months after stopping, about 28% of tirzepatide users regained weight, while 36% kept it off and 36% continued to lose; for semaglutide, ~33% regained, ~32% maintained, and ~35% still lost weight, with a median six‑month change of 0%. The findings suggest durability is possible in routine care and could support a disease-management approach, especially when paired with exercise counseling. Limitations include its observational nature and incomplete accounting for dose and lifestyle factors; results differ from some clinical trial findings and more research is needed to identify who maintains weight loss long-term.

via Reuters|
#drug-discontinuation#glp-1-drugs#health
Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss
health2 months ago

Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss

Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.

via Gizmodo|
#cagrisema#glp-1-therapy#health
FDA Approves Wegovy as First Oral Weight-Loss Pill
health3 months ago

FDA Approves Wegovy as First Oral Weight-Loss Pill

The FDA has approved the first daily oral medication version of Wegovy, a popular weight-loss drug, giving Novo Nordisk an advantage over Eli Lilly, whose similar drug is still under review. The pill, containing semaglutide, has shown significant weight loss in clinical trials and is expected to be available soon, potentially expanding access and reducing costs for obesity treatments.

via CBS News|
#fda-approval#health#novo-nordisk
Pfizer Secures $10 Billion Metsera Deal Amid Industry Shakeup
business5 months ago

Pfizer Secures $10 Billion Metsera Deal Amid Industry Shakeup

Pfizer will acquire Metsera for up to $10 billion after a bidding war with Novo Nordisk, with the deal expected to close soon. Metsera's stock fell over 15% following the announcement, despite its initial surge after going public in January. The acquisition aims to strengthen Pfizer's position in obesity treatment, leveraging Metsera's midstage GLP-1 drug and potential monthly therapies.

via Investor's Business Daily|
#business#buyout#metsera
Novo Nordisk Stock Surges on Successful Triple-Dose Weight Loss Trial
business6 months ago

Novo Nordisk Stock Surges on Successful Triple-Dose Weight Loss Trial

Novo Nordisk's latest clinical trial shows that tripling the dose of its obesity drug semaglutide results in an average of 19% weight loss over 72 weeks, slightly below Eli Lilly's tirzepatide but still promising, as the company aims to strengthen its position in the competitive obesity market. Despite recent challenges and a 60% stock decline over the past year, analysts see potential upside, with NVO rated as a moderate buy and a 23.4% projected increase.

via TipRanks|
#business#clinical-trial#eli-lilly